Last reviewed · How we verify
Phase IIb formulation — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Phase IIb formulation (Phase IIb formulation) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Phase IIb formulation TARGET | Phase IIb formulation | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Phase IIb formulation CI watch — RSS
- Phase IIb formulation CI watch — Atom
- Phase IIb formulation CI watch — JSON
- Phase IIb formulation alone — RSS
Cite this brief
Drug Landscape (2026). Phase IIb formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-iib-formulation. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab